Acupuncture for Ischemic Post-stroke Depression

Comparison of Acupuncture and Fluoxetine for of Ischemic Post-stroke Depression:A Multicentre Randomized Controlled Trial

This is a multicentre, single Blind ,randomized controlled clinical trial in ischemic post-stroke depression patients.The participants will be allocated randomly in either of the two groups: verum acupuncture plus placebo medication group or sham acupuncture plus true medication group. On the hypothesis that acupuncture intervention could produce the same therapeutic effects as antidepressants. The investigators also hypothesized that acupuncture would be associated with minimal side effects.

Study Overview

Detailed Description

Aim: To observe the curative effect of acupuncture in the treatment of Ischemic Post-Stroke Depression. Design: A multicentre,open-label randomized controlled trial will be performed in Tianjin and Beijing . Two hundred and eight participants with Ischemic Post-Stroke Depression patients were randomly divided into two groups which were both given basic treatment of stroke. The acupuncture group was given Tiaoshenkaiqiao acupuncture therapy and placebo,while the control group was treated with fluoxetine tablets and sham acupoint acupuncture treatment. Evaluated the clinical efficacy of the two groups with Hamilton Depression Scale(HAMD), Barthel Index (BI),Treatment Emergent Symptom Scale,(TESS ),Clinical Global Impression Scale(CGI) respectively before treatment, the second weekend of treatment ,the fourth weekend of treatment, the eighth weekend of treatment, the twelfth weekend of treatment. And observed the adverse reaction of the two groups.

Each participants will receive 36 sessions of acupuncture in 12 weeks, with a duration of 30 minutes in a session. After all the treatments were accomplished, there will be one follow-ups in the 24th week.

Study Type

Interventional

Enrollment (Anticipated)

208

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China
        • Beijing Hospital of Traditional Chinese Medicine
    • Tianjin
      • Tianjin, Tianjin, China, 300193
        • First Affiliated hospital of Tianjin University of TCM
      • Tianjin, Tianjin, China
        • Tianjin Academy of Tradional Chinese Medicine Afflicated Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • in accordance with diagnosis of ischemic stroke in International Classification of Diseases-10 163, (ICD-10 163);
  • diagnosis of a major depressive episode according to the depression module of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)or Chinese Classification and Diagnostic Criteria of Mental Disorders-3(CCMD-3)
  • age of a subject is between 40 and 80 years old, male or female;
  • most recently experience an ischemic post-stroke depression and recent (<6 months);
  • conscious, examination cooperation, without aphasia and severe cognitive impairment;
  • capacity to provide written consent for both research assessment and treatment.

Exclusion Criteria:

  • participation in any clinical trial within the previous or taking antidepressant treatment 2 weeks prior to baseline;
  • presence of severe cognitive dysfunction, indicated the Mini-mental State Examination (MMSE) score of < 17
  • presence of severe aphasia;
  • had a history of psychiatric illness or depression
  • impaired hepatic , renal function., hematological systems and so on;
  • those who can not cooperate with treatment;
  • pregnant women or women in lactation
  • presence of another chronic disorder, including chronic alcoholism or durg abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: traditional acupuncture & placebo
Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.

Patients will be treated at Renzhong(Du26), Yintang(EX-HN3)、accupuncture Shangxing(DU23)penetrate to Baihui(DU20),Sishencong(EX-HN1); Neiguan(PC6),Sibai(ST2),Fengchi(GB20)and Sanyinjiao(SP6)in bilateral;Jianyu(LI15),Quchi(LI11),Shousanli(LI10),Hegu(LI 4), Fengshi (GB31),Xuehai(SP10) ,Zusanli(ST36)、Taichong(LR 3) of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).

The acupoints are inserted at the depth of 20-30mm except Renzhong(Du26), Sibai(ST2), Sishencong(EX-HN1)are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.

Placebo was given for 12 consecutive weeks.
Active Comparator: sham-acupoint acupuncture & fluoxetine
Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.

Jianliao(SJ14),Tianquan(PC2),Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze(PC3),Kongzui(LI6),Zhigou(SJ6),Zhongzhu(SJ3),Futu(ST32),Jimen (SP11),Yinshi (ST33),Liangqiu(ST34),Shangjuxu(ST37),Xiajuxu(ST39),Xiyangguan(GB33),Ligou(LR5),Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting (ST44) of the hemiplegia side.

• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting (ST44)are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.

Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
17-item Hamilton Depression Scale( HAMD-17)
Time Frame: 12 weeks
Depression symptoms are primarily measured using the 17-item Hamilton Depression Scale (HAMD-17)
12 weeks
Barthel Index (BI)
Time Frame: 12 weeks
physical outcomes will be measured using Barthel Index (BI)
12 weeks
Clinical Global Impression (CGI)
Time Frame: 12 weeks
Clinical Global Impression (CGI) would also be measured by clinician
12 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Self-Rating Depression Scale(SDS)
Time Frame: 12 weeks
12 weeks
Treatment Emergent Symptom Scale,(TESS )
Time Frame: 12 weeks
12 weeks
Stroke diagnosis and evaluation criteria of Traditional Chinese Medicine(TCM)
Time Frame: 12 weeks
12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ratio of NAA/Cr,Cho/Cr,mI/Cr by Magnetic Resoance Spectroscopy(MRS)
Time Frame: 12 weeks
Compare the ratio of NAA/Cr,Cho/Cr,mI/Cr in brain bilateral dorsolateral prefrontal, anterior cingulate alter brain metabolism after treatment.
12 weeks
Determination of the content change of cytokines IL-1β, IL-6, TNF-α, BDNF in plasma
Time Frame: 12 weeks
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

December 31, 2019

Study Registration Dates

First Submitted

June 8, 2015

First Submitted That Met QC Criteria

June 15, 2015

First Posted (Estimate)

June 16, 2015

Study Record Updates

Last Update Posted (Actual)

February 24, 2021

Last Update Submitted That Met QC Criteria

February 23, 2021

Last Verified

February 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-stroke Depression

Clinical Trials on acupuncture

3
Subscribe